Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
E5 peptide
- Development stage
- Preclinical
- Lead developer
- Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
E5 is a novel synthetic peptide antagonist of the C-X-C chemokine receptor type 4 (CXCR4) developed by the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College. It is specifically designed for the treatment of acute myeloid leukemia (AML). The peptide functions by disrupting the CXCR4/CXCL12 signaling axis, which is essential for the adhesion, migration, and homing of leukemic cells within the protective bone marrow microenvironment. By inhibiting this interaction, E5 mobilizes leukemic cells into the peripheral blood, thereby increasing their sensitivity to chemotherapeutic agents. Preclinical research has also evaluated a micelle-encapsulated formulation, M-E5, which enhances the peptide's solubility and therapeutic profile, demonstrating prolonged survival and reduced organ burden in AML mouse models.
- Other names
- M-E5M-E-5M-E 5
02
Targets
CXCR4 (C-X-C motif chemokine receptor 4)
Beyond the preview
Go deeper on E5 peptide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on E5 peptide.